June 02, 2020
Acadia Pharmaceuticals escaped part of the securities fraud claims lodged in a proposed class action over its alleged cover-up of fatality risks associated with its Parkinson's disease treatment, but it must still face the bulk of the suit, a California federal court ruled Monday.
June 10, 2019
Acadia Pharmaceuticals on Friday sought to dismiss a proposed class action accusing it of inflating its stock price by hiding safety risks connected to its medication for hallucinations and delusions, telling a California federal judge that a government investigation into reported patient deaths confirmed the treatment was safe.
February 27, 2019
Pomerantz LLP has been appointed as lead counsel in a proposed securities fraud class action alleging Acadia Pharmaceuticals Inc. inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its flagship drug used to treat hallucinations and delusions, Nuplazid.
July 20, 2018
An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its treatment for hallucinations and delusions.